CFO and SVP IP for Know Labs www.knowlabs.co, a NYSE-listed medical device company (Ticker: KNW) focused on commercializing a new paradigm for non-invasive, real-time monitoring of analytes in the human body, such as glucose, ketones, metabolites, hormones, etc., powered by a patented radio frequency (RF) dielectric spectroscopy technology utilizing machine learning / artificial intelligence (AI) algorithms. Market focus is on clinical diagnostics and predictive health.

SummaryOver 35 years of experience at the intersection of IP-related investment banking, equity capital markets and the forecasting of emerging new technologies. Investment banking focus on providing public and private equity financing and M&A advisory services to mid-to-late stage private and small-cap public companies with promising disruptive technologies and strong intellectual property (IP). Innovative approaches in monetizing strategic patent portfolios through a variety of transaction types and deal structures — including corporate joint ventures, M&A and IP spin-offs into private or public companies.Industry ExperienceSignificant career experience across TMT, health care, consumer and environmental sectors, having managed over 200 technology financings raising over $4 billion. Core Competencies/Select Clients/TransactionsCore competencies include IP advisory, institutional equity and debt financings, IPOs / SSOs, M&A and strategic corporate advisory services.Select Financing and Advisory Clients and Transactions include: - Large Multinational Healthcare Company (Venture Investment, IP Development, M&A)- Large Multinational Telecommunications Company (M&A Advisory)- Large Multinational Telecommunications Company (IP Spinout)- Leading US Professional Sports Organization & UK-Listed Company (IP Joint-Venture)- $40 Million Market Cap Medical Device Company (Growth Capital)- $80 Million Market Cap Biotech Company (M&A / Growth Capital)- $130 Million Market Cap Biometric Cloud Company (Growth Capital / Corporate Development)Other:CNBC, 2011: Eastman Kodak Strategic IP Value: https://youtu.be/G7b9c66NMioBloomberg, 2010: Nortel IP Value https://www.bloomberg.com/news/articles/2010-05-26/nortel-4-489-patent-national-treasure-may-draw-1-1-billion-to-pay-debtsFINRA Licenses: Series 7, 24, 63, 72, 79, 86 and 87

Outsourced innovation, de novo IP development programs and patent quality services for global technology and life sciences companies in the US, Europe and Asia to create high quality, commercially relevant patented inventions that complement partners' internal R&D efforts. Clients included Philips, Microsoft, Google, Apple, HP, GE, Sony, Samsung, Panasonic, NEC, Fujitsu, Nokia, United Technologies, AstraZeneca, Novartis, Biogen, 3M, Alcoa, Visa and NFL Players Association.

IP-driven investment banking and IP equity research for institutional investors. Research focused on competitive IP analysis (PatentVest), disruptive technologies (ACO, DRTK, HDWR, SINA, TSLA, BYD, etc) and fundamentally-based shorts (Fannie Mae, ShortWatch). Research clients included over one-third of the Institutional Investor 300.

The Analytiq Group / RDEX Resarch, an institutional equity research firm focused solely on patent research and competitive IP analysis covering over 600 public companies and independently ranked for alpha in the top 10% of all ranked U.S. equity research firms by Integrity Research Associates and Investars from 2002-2005.RDEX Research Global TechWatch - quantitative IP research and analysis ranked for alpha in the 99th percentile by Investars 2002-2005 (3 years) with an average return of +1,738 bps for 634 companies vs. Russell 2000 benchmark against all sell-side equity research firms covering more than 500 companies.

Managing Director, Head of Equity Capital MarketsE*Offering, the investment bank of E*Trade, funded by General Atlantic, Softbank , NEA and Battery Ventures, E*Offering was ranked by IDD as #1 internet investment bank with 30% market share and involvement in nearly 1 out of 2 internet IPOs from 1999 to 2000. Acquired by Wit / Soundview for $330 million in 2000.

Head of Institutional Equity Sales

Private Client Services